ArticleEuropean urology oncology2022

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.

Michael A Gorin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.